Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 884604-91-5
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of velaglucerase during breastfeeding. Velaglucerase is a synthetic form of beta-glucocerebrosidase, which is a normal component of human milk, but has an identical amino acid sequence to the normal enzyme. Studies with other forms of the enzyme have found very low levels of the enzyme in breastmilk. Absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract.[1,2] A limited amount of data support the safety of breastfeeding with alglucerase (the placenta-derived form of the enzyme) and imiglucerase (another biosynthetic form of the enzyme). An international panel of clinicians from 9 centers that treat Gaucher's disease reported that, breastfeeding complications were less frequent in mothers who were treated with alglucerase or imiglucerase postpartum than in untreated mothers with Gaucher's disease. Consider limiting the duration of breastfeeding to about 6 months to avoid excessive bone loss in the nursing mother.[2,3]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Belmatoug N. Considerations for pregnant patients with Gaucher disease: challenges for the patient and physician. Clin Ther. 2009;31 Suppl. 3:S192–3. [CrossRef]
- 2.
- Zimran A, Morris E, Mengel E, et al. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Molec Dis. 2009;43:264–88. [PubMed: 19502088]
- 3.
- Granovsky-Grisaru S, Belmatoug N, vom Dahl S, et al. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol. 2011;156:3–8. [PubMed: 21269752]
Substance Identification
Substance Name
Velaglucerase Alfa
CAS Registry Number
884604-91-5
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- PubMedLinks to PubMed
- Review Alglucerase.[Drugs and Lactation Database (...]Review Alglucerase.. Drugs and Lactation Database (LactMed®). 2006
- Review Imiglucerase.[Drugs and Lactation Database (...]Review Imiglucerase.. Drugs and Lactation Database (LactMed®). 2006
- Review Taliglucerase Alfa.[Drugs and Lactation Database (...]Review Taliglucerase Alfa.. Drugs and Lactation Database (LactMed®). 2006
- Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.[J Immunol Methods. 2011]Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA. J Immunol Methods. 2011 Oct 28; 373(1-2):45-53. Epub 2011 Aug 6.
- Review Velaglucerase alfa for the management of type 1 Gaucher disease.[Clin Ther. 2012]Review Velaglucerase alfa for the management of type 1 Gaucher disease.Morris JL. Clin Ther. 2012 Feb; 34(2):259-71. Epub 2012 Jan 20.
- Velaglucerase Alfa - Drugs and Lactation Database (LactMed®)Velaglucerase Alfa - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...